Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05152264
Other study ID # 274998
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 12, 2021
Est. completion date December 2025

Study information

Verified date November 2021
Source Göteborg University
Contact Paulin Andréll, MD, PhD
Phone +46-31-3438259
Email paulin.andrell@gu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study evaluates the effect of TENS (transcutaneous electrical nerve stimulation) as add-on treatment compared with conventional analgesic treatment in patients with endometriosis-related chronic pain. Patients with frequent pain and high pain intensity will be randomized to additional treatment with TENS or conventional treatment for 8 weeks to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment.


Description:

Endometriosis affects approximately one in ten women of childbearing age and may involve both acute pain related to the menstrual cycle and chronic pain. Usual analgesic therapy is often inadequate and/or involves unacceptable side effects and risks with long-term use. Transcutaneous electrical nerve stimulation (TENS) is a patient controlled treatment for pain relief with few side-effects. To date there is limited knowledge of how TENS treatment should be carried out for optimal pain relief in this patient group. The aim of the study is asses the effect of TENS as add-on treatment compared with conventional analgesic treatment in patients with endometriosis-related chronic pain. Patients with frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) will be randomized to additional treatment with TENS or conventional treatment for 8 weeks in order to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment in chronic endometriosis-related pain. Prior to start of TENS treatment, all patients receive education on chronic endometriosis-related pain and TENS treatment. Study participants will be asked to participate in a qualitative follow-up within the study including a semi-structured individual interview (n=10-15) before intervention and a semi-structured focus group (n=9-15) interview after completion of TENS treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2025
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Age =18 years - Consents to participation in the study - Verified endometriosis (by laparoscopy or ultrasound). - Chronic endometriosis-related pain (> 3 months), available for TENS treatment - Functioning, stable endometriosis-specific hormonal drug therapy. The endometriosis-specific drug therapy must be unchanged for the last 3 months and no gynecological surgical procedures for the treatment of endometriosis are planned during the next 7 months (during study participation). The endometriosis-specific drug therapy does not refer to analgesic therapy for symptom relief of endometriosis-related pain. Exclusion Criteria: - Patient with inability to understand and use written and spoken Swedish - Patient with pacemaker and/or ICD or other electronic implants - Patient with impaired sensation over the painful area - Malignant disease with an expected survival <12 months - Alcohol or substance abuse - Serious untreated psychiatric illness and/or psychological condition that is the primary determinant of the patient's condition - Participating in another intervention study with possible impact on current study outcome measures - Patient who is using >90 morphine equivalents/day - Patient who is electro-acupuncture - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcutaneous electrical nerve stimulation (TENS)
Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
Other:
Conventional analgesic treatment
Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.

Locations

Country Name City State
Sweden Pain Centre, Department of Anaesthesiology and Intensive Care Medicine Östra, Sahlgrenska University Hospital, Region Västra Götaland Gothenburg

Sponsors (2)

Lead Sponsor Collaborator
Göteborg University Vastra Gotaland Region

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Anxiety, depression Assessed with the Hospital Anxiety and Depression (HAD) scale. The scale consists of 14 items on a four-point response scale ranging from 0-3. Seven items for depression and 7 items for anxiety with a score range from 0-21. For each factor (anxiety or depression), the results are interpreted as follows: < 8 points indicates within normal range, 8-10 points indicates possible and >10 points indicates probable anxiety or depression. 8 weeks after randomization
Other Anxiety, depression Assessed with the Hospital Anxiety and Depression (HAD) scale. The scale consists of 14 items on a four-point response scale ranging from 0-3. Seven items for depression and 7 items for anxiety with a score range from 0-21. For each factor (anxiety or depression), the results are interpreted as follows: < 8 points indicates within normal range, 8-10 points indicates possible and >10 points indicates probable anxiety or depression. 16 weeks after start of TENS treatment
Other Patient treatment satisfaction according to NRS Self-reported treatment satisfaction with regard to pain relief, how acceptable the patient finds the treatment and hospital care. Numeric rating scale (score from 0 to 10, where 0 is described as "not satisfied at all" and 10 as "very satisfied") and numeric rating scale (score from 0 to 10, where 0 is described as "not acceptable at all" and 10 as "very acceptable"). 8 weeks after randomization
Other Patient treatment satisfaction according to NRS Self-reported treatment satisfaction with regard to pain relief, how acceptable the patient finds the treatment and hospital care. Numeric rating scale (score from 0 to 10, where 0 is described as "not satisfied at all" and 10 as "very satisfied") and numeric rating scale (score from 0 to 10, where 0 is described as "not acceptable at all" and 10 as "very acceptable"). 16 weeks after start of TENS treatment
Other Multidimensional Assessment of Interoceptive Awareness The Multidimensional Assessment of Interoceptive Awareness (MAIA) is an 8-scale state-trait questionnaire with 32 items to measure multiple dimensions of interoception by self-report. 8 weeks after randomization
Other Multidimensional Assessment of Interoceptive Awareness The Multidimensional Assessment of Interoceptive Awareness (MAIA) is an 8-scale state-trait questionnaire with 32 items to measure multiple dimensions of interoception by self-report. 16 weeks after start of TENS treatment
Other Return to work Number of patients who return to work part time or full time. 8 weeks after randomization
Other Return to work Number of patients who return to work part time or full time. 16 weeks after start of TENS treatment
Primary Pain intensity Pain intensity according to numeric rating scale (score from 0 to 10, where 0 is described as "no pain" and 10 as "worst pain imaginable") with regard to endometriosis-related chronic pain 8 weeks after randomization
Secondary Pain intensity Pain intensity according to numeric rating scale (score from 0 to 10, where 0 is described as "no pain" and 10 as "worst pain imaginable") with regard to endometriosis-related chronic pain 16 weeks after start of TENS treatment
Secondary Physical activity Minutes of physical activity per week at moderate and vigorous intensity physical activity (MVPA), minutes of sedentary behaviour (SED) assessed by accelerometry 16 weeks after start of TENS treatment
Secondary Self-assessed physical activity Minutes of physical activity per week (physical exercise and daily exercise) and minutes of sedentary behaviour per week. 16 weeks after start of TENS treatment
Secondary Consumption of analgetics Consumption of primary and secondary analgetics including opioid consumption in morphine equivalent doses 8 weeks after randomization
Secondary Consumption of analgetics Consumption of primary and secondary analgetics including opioid consumption in morphine equivalent doses 16 weeks after start of TENS treatment
Secondary Change in pain intensity Pain intensity according to numeric rating scale (score from 0 to 10, where 0 is described as "no pain" and 10 as "worst pain imaginable") with regard to endometriosis-related chronic pain, Likert scale (1= "worse," 2= "unchanged," 3= "slightly improved," 4= "much improved," 5 = "very much improved,"and 6= "completely improved"). 8 weeks after randomization
Secondary Change in pain intensity Pain intensity according to numeric rating scale (score from 0 to 10, where 0 is described as "no pain" and 10 as "worst pain imaginable") with regard to endometriosis-related chronic pain, Likert scale (1= "worse," 2= "unchanged," 3= "slightly improved," 4= "much improved," 5 = "very much improved,"and 6= "completely improved"). 16 weeks after start of TENS treatment
Secondary Health Related Quality of Life (HRQL) according to SF36 Assessed with RAND Short Form 36 (SF36). The 36 items in the questionnaire are grouped into eight subscale scores: physical functioning, role limitations caused by physical problems, bodily pain, general health, energy/vitality, social functioning, role limitations caused by emotional problems and mental health. The subscale scores range from 0-100, the higher score, the better health related quality of life. 8 weeks after randomization
Secondary Health Related Quality of Life (HRQL) according to SF36 Assessed with RAND Short Form 36 (SF36). The 36 items in the questionnaire are grouped into eight subscale scores: physical functioning, role limitations caused by physical problems, bodily pain, general health, energy/vitality, social functioning, role limitations caused by emotional problems and mental health. The subscale scores range from 0-100, the higher score, the better health related quality of life. 16 weeks after start of TENS treatment
Secondary Health Related Quality of Life (HRQL) assessed with EQ-5D Assessed with EQ-5D-5L. The questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
8 weeks after randomization
Secondary Health Related Quality of Life (HRQL) assessed with EQ-5D Assessed with EQ-5D-5L. The questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
16 weeks after start of TENS treatment
Secondary Health Related Quality of Life (HRQL) assessed with EHP 30 Assessed with Endometriosis Health Profile 30. The EHP score indicate the extent of self-reported ill health on each of the 5 domains measured (Pain, Control and powerlessness, Social support, Emotional well-being, Self-image). Each scale is standardised on a scale of 0 - 100, where 0 indicates the best health status through to 100 worst health status. 8 weeks after randomization
Secondary Health Related Quality of Life (HRQL) assessed with EHP 30 Assessed with Endometriosis Health Profile 30. The EHP score indicate the extent of self-reported ill health on each of the 5 domains measured (Pain, Control and powerlessness, Social support, Emotional well-being, Self-image). Each scale is standardised on a scale of 0 - 100, where 0 indicates the best health status through to 100 worst health status. 16 weeks after start of TENS treatment
Secondary General Self-Efficacy Scale The General Self-Efficacy Scale is a 10-item psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life, Likert scale (1= Not at all true 2= Hardly true 3= Moderately true 4= Exactly true) 8 weeks after randomization
Secondary General Self-Efficacy Scale The General Self-Efficacy Scale is a 10-item psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life, Likert scale (1= Not at all true 2= Hardly true 3= Moderately true 4= Exactly true) 16 weeks after start of TENS treatment
Secondary Insomnia Severity Total score from the 7-item Insomnia Severity Index where total score ranges from 0-28 and higher scores indicate greater severity of insomnia. 8 weeks after randomization
Secondary Insomnia Severity Total score from the 7-item Insomnia Severity Index where total score ranges from 0-28 and higher scores indicate greater severity of insomnia. 16 weeks after start of TENS treatment
Secondary Days of sick-leave Number of days of sick-leave 8 weeks after randomization
Secondary Days of sick-leave Number of days of sick-leave 16 weeks after start of TENS treatment
See also
  Status Clinical Trial Phase
Completed NCT04179149 - Enriched Environments in Endometriosis N/A
Completed NCT03654326 - A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034) Phase 2
Recruiting NCT04554693 - The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery Phase 4
Recruiting NCT06214260 - Menstrual Blood Proteomic Profile in Women With Endometriosis (PROTEO-ENDO) Study
Recruiting NCT05978414 - Functional Links Between the Temporomandibular Joint and the Pelvis in Gynecology N/A
Recruiting NCT06414083 - Histologic Comparison of Ablative Techniques for Endometriosis N/A
Completed NCT04440397 - Relationship Between Endoplasmic Reticulum Stress and Pain in Patients With Endometriosis
Completed NCT04370444 - Pathways for Patient-centered Diagnosis and Management of Endometriosis-associated Deep Dyspareunia N/A
Recruiting NCT05367258 - Umbilical Endometriosis: a Comparison of Medical and Surgical Therapy and Pathogenetic Considerations
Completed NCT05527002 - Thoracic Endometriosis: A Cohort Study
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting NCT04728152 - Evaluation of miRNAs in Endometriosis
Completed NCT04883073 - Impact on Quality of Life of "Endo-App" (ELEA) N/A
Active, not recruiting NCT04204707 - Patient Reported Outcomes After Surgery for Rectal Endometriosis
Completed NCT03692403 - Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain Phase 2
Recruiting NCT06438744 - The Role of Thread Embedding Acupuncture for Pain and Quality of Life in Endometriosis Patients N/A
Recruiting NCT06286371 - Pelvic Neuro-Angiogenesis in Deep Endometriosis N/A
Not yet recruiting NCT04491305 - EHP-5 in Preoperative Assessment in Women With Endometriosis
Recruiting NCT05496218 - Metabolomic Profile in Women With and Without Endometriosis N/A
Recruiting NCT05433909 - Microbiota and Immunoassay in Women With and Without Endometriosis: a Pilot Study N/A